A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients

• Status: Completed
• Trial end date: 2009-06-01

Summary

This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Calcium heparin; Certoparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin